Mylan Launches Hulio Biosimilar Adalimumab in Markets Across Europe

Mylan Launches Hulio (Biosimilar Adalimumab) in Markets Across Europe

13:13 EDT 19 Oct 2018 | FinanzNachrichten

HERTFORDSHIRE, England and PITTSBURGH, Oct. 19, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has initiated the commercial launch of Hulio, a ...

Original Article: Mylan Launches Hulio (Biosimilar Adalimumab) in Markets Across Europe

More From BioPortfolio on "Mylan Launches Hulio (Biosimilar Adalimumab) in Markets Across Europe"